Mankind Pharma Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Mankind Pharma

CMP

2,240.60

+0.40 (0.02%)

  • DRHP
₹1,080

Offer Price

₹ 4,326.36 Cr

Issue Size

₹ 14,040

Min Investment

15.32x

Times Subscribed

13

Lot size

Time Line

  • 25
    Apr 2023
    Open
  • 27
    Apr 2023
    Close
  • 03
    May 2023
    Finalisation of Basis of Allotment
  • 04
    May 2023
    Initiation of Refunds
  • 08
    May 2023
    Transfer of Shares to Demat Account
  • 09
    May 2023
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Increase Covered Market presence including in chronic therapeutic areas

  • Focus on increasing penetration in metro and Class I cities

  • Focus on building alternative channels for growth

  • Grow its consumer healthcare business

  • Continue to develop and invest in digital platforms to enhance doctor engagement

Products & Services

  • The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Strengths

  • scaled domestic focused business with potential for further growth;

  • growing faster than the rate of the IPM with a focus on volume-led growth;

  • diversified portfolio with market leading rankings across key therapeutic areas;

  • established and growing consumer healthcare franchise with brand recall;

  • leveraged its corporate brand to build and scale brands;

Risks

  • The company is subject to extensive government regulations which are also subject to change. If the company fail to comply with the applicable regulations prescribed by the governments and the relevant regulatory agencies, its business, financial condition, cash flows and results of operations will be adversely affected.

  • The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operate its business.

  • Any disruption, slowdown or shutdown in its manufacturing or R&D operations could adversely affect its business, financial condition, cash flows and results of operations.

  • The company inability to accurately forecast demand for its products and manage the company inventory may have an adverse effect on its business, financial condition, cash flows and results of operations.

  • Any failure to maintain and enhance, or any damage to, its brands, product image or reputation could adversely affect the market recognition of, and trust in, the company products.

Company Promoters

Promoters Holding

Issue For IPO
67.29%
Pre Holding

67.29%

Post Holding

-

Top Promoters Holding

Financials

All values in Cr

Mar-2022 Mar-2023 Mar-2022 3-Yr trend
Revenue 7,781.56 (25.20%) 8,749.43 (12.40%) 23.29 (-)
Gross Profit 7,781.56 (25.20%) 8,749.43 (12.40%) 23.29 (-)
Net Income 7,781.56 (25.20%) 8,749.43 (12.40%) 23.29 (-)
Assets 7,781.56 (25.20%) 8,749.43 (12.40%) 23.29 (-)
Liabilities 7,781.56 (25.20%) 8,749.43 (12.40%) 23.29 (-)

Peers

Company Name Revenue (Cr) Net Profit (Cr) Assets (Cr) Liabilities (Cr) ROE EPS BVPS Current Ratio Debt to Assets
Mankind Pharma Ltd 7,781.56 1,433.48 7,289.54 1,134.31 23.29 35.78 153.65 1.92 0.12
Sun Pharmaceuticals Industries Ltd 38,654.49 3,272.73 69,799.87 69,799.87 6.81 13.60 212.84 4.68 0.02
Cipla Ltd 21,763.34 2,516.75 27,101.12 27,101.12 12.07 31.17 261.74 9.28 0.04
Zydus Lifesciences Ltd 15,265.20 4,487.30 27,795.40 27,795.40 26.39 43.83 186.07 16.14 0.25
Torrent Pharmaceuticals Ltd 8,508.04 777.18 13,099.84 13,099.84 13.05 45.93 351.75 5.93 0.67
Alkem Laboratories Ltd 10,634.19 1,645.62 14,069.19 14,069.19 19.05 137.63 740.05 11.69 0.30
J B Chemicals & Pharmaceuticals Ltd 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ERIS Lifesciences Ltd 1,347.04 406.11 2,272.14 2,272.14 21.28 29.89 140.35 17.87 0.02
Ipca Laboratories Ltd 5,829.79 884.08 7,638.86 7,638.86 16.09 34.85 219.51 11.57 0.14
Abbott India Ltd 4,919.27 798.70 4,224.12 4,224.12 28.32 375.86 1,326.96 18.90 0.00
Glaxosmithkline Pharmaceuticals Ltd 3,278.03 1,694.72 4,633.28 4,633.28 63.64 100.04 157.19 36.57 0.00
Dabur India Ltd 10,888.68 1,739.22 12,284.53 12,284.53 20.75 9.81 47.64 14.15 0.10
Procter & Gamble Health Ltd 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Zydus Wellness Ltd 2,009.10 308.87 5,692.18 5,692.18 6.37 48.54 761.28 5.42 0.08

Book Running Managers

  • Axis Capital Ltd
  • IIFL Securities Ltd
  • J.P.Morgan India Pvt Ltd
  • Jefferies India Pvt Ltd
  • Kotak Mahindra Capital Company Ltd

Registrar & Transfer Agent

KFin Techologies Ltd

Karvy Selenium Tow-B,
31&32 Financial Dist,
Nanakramguda - Hyderabad-500032
Phone : 91-40-67162222 Fax: 91-40-23001153/23420814

Company Contact Information

208 Okhla Industrial Estate,
Phase-III,
New Delhi - 110020
Phone : 91-11-47476600 Email : investors@mankindpharma.com www.mankindpharma.com

Offer Related Information

Initial public offering of 40,058,844 equity shares of face value of Re. 1 each ("Equity Shares") of Mankind Pharma Limited ("The Company" or the "Issuer") for cash at a price of Rs. 1,080 per equity share ("Offer Price") aggregating to Rs. 4326.36 crores, comprising an offer for sale of 3,705,443 equity shares aggregating to Rs. 400.18 crores by Ramesh Juneja, 3,505,149 equity shares aggregating to Rs. 378.56 crores by Rajeev Juneja, 2,804,119 equity shares aggregating to Rs. 302.85 crores by... More

News

  • No Data Found.

Take your research to the next level.
Login now to unlock Exclusive Features!

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: